Manuel Baca, PhD 
Vice President, Biologics, Tri-Institutional Therapeutics Discovery Institute

Dafna Bar-Sagi, PhD 
Executive Vice President, Chief Scientific Officer, NYU Grossman School of Medicine

Peter Meinke, PhD 
Director, Tri-Institutional Therapeutics Discovery Institute

David Morrissey, PhD 
VP, Head RNA Accelerator, Pfizer

Marilyn Resh, PhD 
Member Emeritus, Sloan Kettering Institute

Joseph Scandura, MD, PhD 
Scientific Director, Richard T. Silver MPN Center, Weill Cornell Medical College

Manuel Baca, PhD 
Vice President, Biologics, Tri-Institutional Therapeutics Discovery Institute

Craig Crews, PhD 
Executive Director, Yale Center for Molecular Discovery

Barbara Hempstead, MD, PhD 
Dean, Weill Cornell Graduate School of Medical Sciences

Tarun Kapoor, PhD 
Professor, Rockefeller University

Peter Meinke, PhD 
Director, Tri-Institutional Therapeutics Discovery Institute

Dafna Bar-Sagi, PhD
Senior Vice President, Vice Dean for Science, and Chief Scientific Officer, New York University School of Medicine

Catherine Bollard, MD
Director, Center for Cancer and Immunology Research, Children’s Research Institute, Children’s National Health System

Katherine High, MD
Co-Founder, President, and Head of R&D, Spark Therapeutics Inc.

Ivo Lorenz, PhD
Vice President, Biologics, Tri-Institutional Therapeutics Discovery Institute

Joseph Scandura, MD, PhD
Scientific Director, Richard T. Silver MPN Center, Weill Cornell Medicine

Edward Skolnik, MD
Professor, Medicine and Biochemistry and Molecular Pharmacology, New York University School of Medicine

Michael Foley, PhD
Director, Tri-Institutional Therapeutics Discovery Institute

Ivo Lorenz, PhD
Vice President, Biologics, Tri-Institutional Therapeutics Discovery Institute

Gary Schwartz, MD
Deputy Director, Herbert Irving Comprehensive Cancer Center

Edward Skolnik, MD
Director, Division of Nephrology, New York University Langone Medical Center

Neil Stahl, PhD
Executive Vice President, Research and Development, Regeneron Pharmaceuticals

Michael Foley, PhD
Director, Tri-Institutional Therapeutics Discovery Institute

Hyam Levitsky, MD
Executive Vice President and Chief Scientific Officer, Juno Therapeutics

Ivo Lorenz, PhD
Vice President, Biologics, Tri-Institutional Therapeutics Discovery Institute

David Nanus, MD
Chief, Division of Hematology and Medical Oncology, Weill Cornell Medicine

Benjamin Neel, MD, PhD
Director, Laura and Isaac Perlmutter Cancer Center, New York University

Michael Foley, PhD
Director, Tri-Institutional Therapeutics Discovery Institute

Angus Grant, PhD
Corporate Vice President, Business Development, Celgene

Ivo Lorenz, PhD
Vice President, Biologics, Tri-Institutional Therapeutics Discovery Institute

David Nanus, MD
Chief, Division of Hematology and Medical Oncology, Weill Cornell Medicine

Benjamin Neel, MD, PhD
Director, Laura and Isaac Perlmutter Cancer Center, New York University

Juan Harrison
Vice President, Takeda Ventures, Inc.

Nils Lonberg, PhD
Senior Vice President, Immuno-Oncology & Biologics Discovery, Bristol-Myers Squibb

Jeffrey Molldrem, MD
Chief, Section of Transplantation Immunology, Dept. of Stem Cell Transplantation and Cellular Therapy, UT MD Anderson Cancer Center

John Porco, PhD
Director, Chemical Methodology and Library Development Center, Boston University

Michael Foley, PhD
Tri-Institutional Therapeutics Discovery Institute

Thorsten Graef, MD, PhD
Pharmacyclics

Garth Powis, DPhil
Sanford Burnham Medical Research Institute

Raymond Warrell, MD
Relburn-Metabolomics

Jeffrey Aubé, PhD
University of Kansas

Michael Foley, PhD
Broad Institute of MIT and Harvard

Frank Haluska, MD, PhD
Ariad Pharmaceuticals

Raymond Warrell, MD
Relburn

Jeffrey Aubé, PhD
University of Kansas

José Baselga, MD, PhD
Massachusetts General Hospital Cancer Center

Michael Foley, PhD
Broad Institute of MIT and Harvard

Richard van Etten, MD, PhD
Tufts Medical Center Cancer Center

Gideon Bollag, PhD
Plexxikon

Glenn Dranoff, MD
Dana-Farber Cancer Institute, Harvard Medical School

Carl June, MD, PhD
Abramson Family Cancer Research Institute, University of Pennsylvania

Edward Sausville, MD, PhD
Greenebaum Cancer Center, University of Maryland

Beverly Mitchell, MD
Stanford University

Garth Powis, D. Phil
University of Texas MD Anderson Cancer Center

Edward Sausville, MD, PhD
Greenebaum Cancer Center, University of Maryland

Neil Stahl, PhD
Regeneron Pharmaceuticals

Julian Adams, PhD
Infinity Pharmaceuticals

Michael Caligiuri, MD
Ohio State University Comprehensive Cancer Center

Kenneth Cowan, MD, PhD
University of Nebraska Medical Center Eppley Cancer Center

Jerry Collins, PhD
National Cancer Institute

Garth Powis, DPhil
University of Texas MD Anderson Cancer Center

Peter Senter, PhD
Seattle Genetics

Richard Van Etten, MD, PhD
Tufts-New England Medical Center Cancer Center

Roger M. Freidinger, PhD
Merck Research Laboratories

Robert C. Jackson, PhD
Cyclacel (UK)

Peter J. Houghton, PhD
St. Jude Children’s Research Hospital

Gregory L. Verdine, PhD
Dana-Farber Cancer Institute, Harvard Medical School

James Gibbons, PhD
Wyeth Pharmaceuticals

Robert C. Jackson, PhD
Cyclacel, (UK)

Lee Nadler, MD
Dana-Farber Cancer Institute

Eric Rowinsky, MD
ImClone Systems Incorporated

William Kaelin, MD
Dana-Farber Cancer Institute

Nicholas Lydon, PhD
Amgen

Edward Sausville, MD, PhD
Greenebaum Cancer Center, University of Maryland

Daniel Von Hoff, MD
Translational Genomics Institute (TGen)
Arizona Health Sciences Center’s Cancer Therapeutics Program

Christopher P. Austin, MD
National Institutes of Health

Elizabeth Eisenhauer, MD
National Cancer Institute of Canada

Donald W. Kufe, MD
Dana-Farber Cancer Institute

Nicholas Lydon, MD
Amgen

Ross C. Donehower, MD, FACP
Kimmel Cancer Center at Johns Hopkins Oncology Center

Allen Oliff, MD
GlaxoSmithKline Pharmaceuticals

Edward A. Sausville, MD, PhD
National Cancer Institute

Judith Sebolt-Leopold, PhD
Pfizer Global Research and Development